Two senior scientists say National Institutes of Health officials advised them to remove references to mRNA vaccines in grant applications, and they fear the Trump administration will abandon a promising field of medical research.
Should Marty Makary take the reins at the FDA, transitioning from gadfly to the head of an agency that regulates a fifth of the U.S. economy, he would have to engage in the thorny challenges of governing.
The FDA is already limited in policing claims of health benefits by makers of supplements and herbal remedies — a $70 billion industry. Get ready for even less regulation.
Two Senate committees are expected to question Robert F. Kennedy Jr. on how his disproven views of science and medicine qualify him to run the $1.7 trillion, 80,000-employee federal health system.
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.
Inoculation campaigns that protect children and adults from dangerous diseases rely on a delicate web of state and federal laws and programs. If senior officials cast doubt on vaccine safety, the whole system might collapse, especially in red states.
As federal health scientists await an unprecedented takeover by medical skeptics in the second Trump administration, some are said to be preparing résumés or retirement papers.
A Massachusetts woman ended up stranded in the hospital because CVS stopped providing the IV nutrition she needs to survive at home. Without it, she’d starve.
The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.
For decades, the pulse oximeters used in hospitals, ambulances, and homes have underestimated the oxygen needs of darker-skinned patients. The FDA is preparing guidelines to fix that. But will the new rules go far enough?